

Appendix 1. Uterine Cancer Demographics, Incidence, Trends, and Gap Percentage

2001-2020	Count N (%)	2001-2019 AAPC* (95% CI)	2019 incidence[†]	2020 expected[‡]	2020 observed[§]	Gap % (95% CI)	Gap % p-value
Overall	928357 (100%)	0.81# (0.59, 1.04)	28.14	28.28	25.65	-9.31 (-10.00, -8.62)	0.180
Age Group							
20-29	4671 (0.5%)	3.16# (2.71, 3.61)	1.53	1.57	1.32	-16.27 (-16.52, -15.76)	<0.001
30-34	9685 (1.0%)	2.85# (2.44, 3.26)	6.08	6.25	5.56	-11.06 (-11.45, -10.67)	<0.001
35-39	18285 (2.0%)	2.67# (2.37, 2.96)	10.97	11.27	10.13	-10.08 (-10.31, -9.78)	<0.001
40-44	31196 (3.4%)	1.88# (1.58, 2.19)	17.78	18.11	15.82	-12.62 (-12.91, -12.37)	<0.001
45-49	52634 (5.7%)	0.96# (0.50, 1.42)	28.90	29.46	25.18	-14.55 (-15.38, -13.67)	<0.001
50-54	95846 (10.3%)	0.42 (-0.40, 1.24)	48.91	48.73	43.60	-10.52 (-12.66, -8.31)	0.741
55-59	143779 (15.5%)	0.81# (0.50, 1.12)	77.63	77.19	72.11	-6.57 (-7.49, -5.64)	0.235
60-64	157644 (17.0%)	0.99# (0.54, 1.43)	101.51	100.44	92.32	-8.09 (-9.18, -6.97)	0.075
65-69	143063 (15.4%)	1.32# (0.97, 1.66)	118.45	119.08	106.30	-10.73 (-11.29, -10.16)	0.093
70-74	106463 (11.5%)	1.27# (0.71, 1.83)	113.16	115.35	104.29	-9.59 (-9.75, -9.43)	<0.001
75-79	75017 (8.1%)	0.40 (0.01, 0.79)	94.58	95.83	88.29	-7.85 (-8.13, -7.58)	<0.001
80-84	50073 (5.4%)	-0.54 (-1.01, -0.07)	75.53	76.13	72.77	-4.41 (-5.00, -3.81)	0.017
85+	39816 (4.3%)	-1.71# (-1.96, -1.46)	49.47	48.62	45.32	-6.78 (-7.01, -6.55)	<0.001
Race							
Asian/Pacific Islander	32975 (3.6%)	2.35# (2.11, 2.59)	22.21	22.73	20.00	-12.00 (-12.22, -11.79)	<0.001
Black	98058 (10.6%)	2.15# (1.74, 2.57)	29.16	29.21	27.20	-6.87 (-10.25, -3.38)	0.930
Hispanic	79216 (8.5%)	2.11# (1.85, 2.36)	26.83	27.39	23.38	-14.63 (-14.84, -14.42)	<0.001
White	704245 (75.9%)	0.53# (0.30, 0.76)	28.11	28.03	25.61	-8.64 (-9.38, -7.89)	0.441
None of the Above or Unknown	13863 (1.5%)	1.94# (1.26, 2.61)	55.06	57.37	58.87	2.62 (0.89, 4.30)	<0.001
U.S. Division							
New England	56361 (6.1%)	0.23 (0.01, 0.46)	29.78	29.85	25.72	-13.83 (-14.02, -13.64)	0.044
Middle Atlantic	162526 (17.5%)	0.62¶ (0.19, 1.06)	32.09	31.94	29.56	-7.47 (-9.82, -5.05)	0.711

Tran N, Chan J, Stewart C, Johnson C, Darcy K, Tian C, et al. Trends in uterine cancer cases after the coronavirus disease 2019 (COVID-19) pandemic. *Obstet Gynecol* 2024;144.

The authors provided this information as a supplement to their article.

©2024 American College of Obstetricians and Gynecologists.

East North Central	142324 (15.3%)	0.91 [#] (0.73, 1.09)	30.48	30.76	27.68	-10.02 (-10.18, -9.87)	<0.001
West North Central	68108 (7.3%)	0.87 [#] (0.66, 1.07)	29.46	29.72	26.48	-10.90 (-11.06, -10.70)	<0.001
South Atlantic	182423 (19.7%)	1.26 [#] (0.70, 1.82)	26.67	27.11	24.71	-8.86 (-9.01, -8.70)	<0.001
East South Central	42323 (4.6%)	1.80 [#] (1.57, 2.03)	25.52	25.98	22.10	-14.94 (-15.14, -14.75)	<0.001
West South Central	83873 (9.0%)	1.38 [#] (0.83, 1.94)	24.80	25.33	22.76	-10.14 (-10.36, -9.92)	<0.001
Mountain	49097 (5.3%)	0.92 (-0.10, 1.96)	24.11	24.30	21.84	-10.15 (-10.65, -9.64)	0.009
Pacific	141322 (15.2%)	1.06 [#] (0.44, 1.68)	28.44	28.90	26.15	-9.52 (-9.70, -9.35)	<0.001

* Average Annual Percent Change

† Incidence per 100,000 women

‡ Expected Uterine Cancer Incidence per 100,000 women in 2020

§ Observed Uterine Cancer Incidence per 100,000 women in 2020

|| p-value less than 0.05

¶ p-value less than 0.01

p-value less than 0.001

Tran N, Chan J, Stewart C, Johnson C, Darcy K, Tian C, et al. Trends in uterine cancer cases after the coronavirus disease 2019 (COVID-19) pandemic. *Obstet Gynecol* 2024;144.

The authors provided this information as a supplement to their article.

©2024 American College of Obstetricians and Gynecologists.

Appendix 2. Uterine Cancer Stage, Histology, Incidence, Trends, and Gap Percentage

2001-2020	Count N (%)	2001-2019 AAPC ¹ (95% CI)	2019 incidence ²	2020 expected ³	2020 observed ⁴	Gap % (95% CI)	Gap % p-value
Overall	928357 (100%)	0.81 [#] (0.59, 1.04)	28.14	28.28	25.65	-9.31 (-10.00, -8.62)	0.180
Stage							
Local	624136 (67.2%)	0.81 [¶] (0.19, 1.42)	19.36	19.25	17.49	-9.15 (-11.69, -6.54)	0.658
Regional	175791 (18.9%)	0.80 (-0.72, 2.36)	4.60	4.67	4.26	-8.70 (-15.93, -0.85)	0.685
Distant	78830 (8.5%)	2.71 [#] (2.48, 2.94)	2.70	2.78	2.68	-3.56 (-3.78, -3.34)	<0.001
Cell Type							
Epithelial carcinoma	889746 (95.8%)	0.84 [#] (0.58, 1.09)	26.91	27.04	24.49	-9.42 (-10.18, -8.66)	0.237
Endometrioid carcinoma (EC)	675090 (72.7%)	0.53 [¶] (0.20, 0.87)	20.49	20.69	18.50	-10.60 (-10.70, -10.50)	<0.001
Grade 1 EC	310500 (33.4%)	2.03 [#] (0.82, 3.26)	11.65	13.30	10.53	-20.83 (-26.22, -15.05)	0.001
Grade 2 EC	187484 (20.2%)	0.06 (-0.74, 0.87)	5.64	6.85	5.10	-25.5 (-30.16, -20.52)	<0.001
Grade 3 EC	86755 (9.3%)	-0.93 (-2.06, 0.21)	2.29	2.55	2.06	-19.16 (-26.38, -11.23)	0.030
Serous carcinoma	61295 (6.6%)	4.70 [#] (3.80, 5.60)	2.31	2.41	2.17	-9.69 (-11.01, -8.39)	<0.001
Clear cell carcinoma	12731 (1.4%)	1.16 [#] (0.48, 1.85)	0.40	0.41	0.39	-6.21 (-7.61, -4.92)	0.002
Carcinosarcoma	46445 (5.0%)	1.51 [#] (1.27, 1.74)	1.40	1.43	1.26	-11.79 (-12.02, -11.59)	<0.001
Mixed cell adenocarcinoma	43017 (4.6%)	8.29 [#] (4.06, 12.70)	1.21	1.09	1.13	4.35 (-11.38, 22.93)	0.180
Other epithelial carcinoma	51168 (5.5%)	-3.14 [#] (-3.80, -2.46)	1.09	1.06	1.04	-1.41 (-1.64, -1.12)	<0.001
Mesenchymal cancer	33365 (3.6%)	0.44 [¶] (0.19, 0.69)	1.04	1.05	0.96	-8.69 (-8.90, -8.47)	0.002
Leiomyosarcoma	18268 (2.0%)	0.56 [¶] (0.23, 0.89)	0.56	0.58	0.51	-12.17 (-12.45, -11.88)	0.002
Low-grade ESS	4242 (0.5%)	-0.80 (-1.61, 0.02)	0.15	0.14	0.12	-15.22 (-15.95, -14.47)	0.054
High-grade ESS	5357 (0.6%)	-1.22 [¶] (-2.09, -0.35)	0.15	0.12	0.14	11.79 (9.55, 13.54)	0.003
Endometrial Stromal Sarcoma (ESS)	9599 (1.0%)	-0.93 [#] (-1.38, -0.48)	0.30	0.27	0.26	-3.72 (-4.17, -3.27)	<0.001
Other mesenchymal cancer	5498 (0.6%)	2.69 [#] (2.10, 3.28)	0.21	0.20	0.19	-5.70 (-6.29, -5.10)	<0.001
Adenosarcoma	4462 (0.5%)	2.11 [#] (0.86, 3.38)	0.16	0.18	0.17	0.00 (-7.26, 7.25)	0.059
Choriocarcinoma or others	783 (0.1%)	1.63 (0.07, 3.22)	0.03	0.03	0.03	-2.04 (-4.00, -2.04)	0.042

* Average Annual Percent Change
 † Incidence per 100,000 women
 ‡ Expected Uterine Cancer Incidence per 100,000 women in 2020
 § Observed Uterine Cancer Incidence per 100,000 women in 2020
 || p-value less than 0.05

Tran N, Chan J, Stewart C, Johnson C, Darcy K, Tian C, et al. Trends in uterine cancer cases after the coronavirus disease 2019 (COVID-19) pandemic. *Obstet Gynecol* 2024;144.

The authors provided this information as a supplement to their article.

©2024 American College of Obstetricians and Gynecologists.

Appendix 3. Uterine Cancer Incidence, Trends, and Gap Percentage by Histology and Race

2001-2020	Count N (%)	2001-2019 AAPC¹ (95% CI)	2019 incidence²	2020 expected³	2020 observed⁴	Gap % (95% CI)	Gap % p-value
Overall	928357 (100.0%)	0.81 [#] (0.59, 1.04)	28.14	28.28	25.65	-9.31 (-10.00, -8.62)	0.180
Epithelial carcinoma	889746 (95.8%)						
Asian/Pacific Islander	31276 (3.4%)	2.40 [#] (2.17, 2.64)	21.16	21.66	19.00	-12.33 (-12.56, -12.15)	<0.001
Black	90265 (9.7%)	2.34 [#] (2.18, 2.5)	27.03	27.66	25.09	-9.28 (-9.44, -9.15)	<0.001
Hispanic	74550 (8.0%)	2.17 [#] (1.92, 2.43)	25.44	25.99	22.18	-14.68 (-14.89, -14.46)	<0.001
White	680438 (73.3%)	0.56 [#] (0.30, 0.81)	27.08	26.99	24.66	-8.63 (-9.45, -7.79)	0.425
Endometrioid carcinoma	675090 (72.7%)						
Asian/Pacific Islander	24072 (2.6%)	2.27 [#] (1.97, 2.57)	16.22	16.59	14.83	-10.59 (-10.84, -10.34)	<0.001
Black	50380 (5.4%)	1.61 [#] (1.43, 1.79)	14.52	14.76	13.17	-10.77 (-10.91, -10.60)	<0.001
Hispanic	56413 (6.1%)	2.36 [#] (1.72, 3.01)	19.29	20.59	16.61	-19.31 (-23.78, -14.58)	0.028
White	533575 (57.5%)	0.42 [¶] (0.10, 0.73)	21.53	21.71	19.44	-10.44 (-10.53, -10.34)	<0.001
Serous carcinoma	61295 (6.6%)						
Asian/Pacific Islander	2167 (0.2%)	6.50 [#] (5.59, 7.41)	1.98	2.11	1.51	-28.51 (-29.13, -27.88)	<0.001
Black	14490 (1.6%)	5.91 [#] (3.99, 7.87)	5.48	5.70	5.29	-7.15 (-9.00, -5.23)	0.001
Hispanic	4980 (0.5%)	5.43 [#] (4.49, 6.37)	2.11	2.23	2.12	-5.00 (-5.86, -4.13)	<0.001
White	38940 (4.2%)	3.84 [#] (2.82, 4.87)	1.85	1.85	1.73	-6.25 (-12.82, 0.78)	0.902
Clear cell carcinoma	12731 (1.4%)						
Asian/Pacific Islander**	483 (0.1%)	-	-	-	-	-	-
Black	2325 (0.3%)	2.18 [#] (1.26, 3.12)	0.77	0.79	0.70	-11.18 (-12.21, -10.12)	<0.001
Hispanic	1092 (0.1%)	1.99 [¶] (0.57, 3.43)	0.40	0.41	0.34	-17.36 (-18.03, -15.97)	0.009
White	8672 (0.9%)	0.47 (0.03, 0.91)	0.35	0.35	0.35	-1.76 (-2.33, -1.47)	0.039
Carcinosarcoma	46445 (5.0%)						
Asian/Pacific Islander	1466 (0.2%)	1.68 [¶] (0.49, 2.90)	0.95	0.96	0.94	-1.92 (-2.86, -0.97)	0.009

Tran N, Chan J, Stewart C, Johnson C, Darcy K, Tian C, et al. Trends in uterine cancer cases after the coronavirus disease 2019 (COVID-19) pandemic. *Obstet Gynecol* 2024;144.

The authors provided this information as a supplement to their article.

©2024 American College of Obstetricians and Gynecologists.

Black	11230 (1.2%)	1.70 [#] (1.21, 2.19)	3.23	3.29	2.98	-9.45 (-9.96, -9.07)	<0.001
Hispanic	3705 (0.4%)	2.68 [#] (1.97, 3.40)	1.33	1.36	1.17	-14.39 (-15.02, -13.75)	<0.001
White	29526 (3.2%)	1.03 [#] (0.74, 1.32)	1.15	1.17	1.02	-12.39 (-12.62, -12.08)	<0.001
Mixed cell adenocarcinoma	43017 (4.6%)						
Asian/Pacific Islander**	1493 (0.2%)	-	-	-	-	-	-
Black	4770 (0.5%)	9.44 [#] (6.01, 12.98)	1.33	1.31	1.31	-0.70 (-3.42, 2.55)	0.465
Hispanic	3254 (0.4%)	7.02 [#] (3.50, 10.65)	0.93	0.92	0.84	-9.12 (-11.7, -6.39)	0.850
White	33016 (3.6%)	8.55 [#] (4.13, 13.16)	1.25	1.12	1.18	5.63 (-11.31, 25.82)	0.174
Mesenchymal tumors	33365 (3.6%)						
Asian/Pacific Islander	1444 (0.2%)	1.53 (0.34, 2.74)	0.90	0.91	0.84	-8.08 (-9.00, -6.19)	0.015
Black	6742 (0.7%)	1.37 [#] (0.82, 1.91)	1.80	1.82	1.81	-0.51 (-1.01, 0.00)	<0.001
Hispanic	3953 (0.4%)	0.82 (0.22, 1.43)	1.17	1.18	0.98	-16.86 (-17.33, -16.38)	0.010
White	20114 (2.2%)	-0.28 (-0.61, 0.04)	0.87	0.87	0.77	-11.30 (-11.61, -10.98)	0.081
Leiomyosarcoma	18268 (2.0%)						
Asian/Pacific Islander	825 (0.1%)	1.40 (-6.17, 9.58)	0.54	0.57	0.48	-17.74 (-22.73, -10.53)	0.184
Black	4090 (0.4%)	1.83 [#] (1.32, 2.34)	1.17	1.19	1.10	-7.39 (-7.75, -7.03)	<0.001
Hispanic	2207 (0.2%)	0.76 (-0.17, 1.70)	0.65	0.66	0.55	-15.46 (-16.33, -15.03)	0.103
White	10579 (1.1%)	-0.44 (-0.91, 0.02)	0.44	0.44	0.38	-14.55 (-14.95, -14.35)	0.061
Endometrial Stromal Sarcoma	9599 (1.0%)						
Asian/Pacific Islander**	387 (0%)	-	-	-	-	-	-
Black	1398 (0.2%)	-0.75 (-1.67, 0.18)	0.28	0.27	0.36	30.51 (28.33, 30.51)	0.106
Hispanic	1116 (0.1%)	-0.74 (-1.92, 0.47)	0.27	0.27	0.24	-12.35 (-13.41, -11.25)	0.213
White	6329 (0.7%)	-1.05 [¶] (-1.71, -0.40)	0.28	0.28	0.24	-12.73 (-13.38, -12.41)	0.004
Adenosarcoma	4462 (0.5%)						

Tran N, Chan J, Stewart C, Johnson C, Darcy K, Tian C, et al. Trends in uterine cancer cases after the coronavirus disease 2019 (COVID-19) pandemic. *Obstet Gynecol* 2024;144.

The authors provided this information as a supplement to their article.

©2024 American College of Obstetricians and Gynecologists.

Asian/Pacific Islander**	200 (0.02%)	-	-	-	-	-	-
Black	762 (0.1%)	3.22 [#] (1.62, 4.85)	0.27	0.28	0.25	-11.67 (-13.11, -10.17)	0.001
Hispanic**	517 (0.1%)	-	-	-	-	-	-
White	2845 (0.3%)	1.15 [¶] (0.43, 1.87)	0.14	0.15	0.16	8.45 (7.69, 9.22)	0.003
Choriocarcinoma or others	783 (0.1%)						
Asian/Pacific Islander**	41 (0.004%)	-	-	-	-	-	-
Black**	205 (0.02%)	-	-	-	-	-	-
Hispanic**	177 (0.02%)	-	-	-	-	-	-
White**	322 (0.03%)	-	-	-	-	-	-

The categories for the following histologies: Grades 1-3 of Endometrioid Carcinoma, Other Epithelial Carcinoma, Low or High Grade ESS, Other Mesenchymal Cancer were not included in this table. The category for race, "None of the Above or Unknown" was also excluded from this table.

- : Uterine cancer incidence data was too small to create trend analyses (Average Annual Percent Change, 95% Confidence Intervals, etc.)

* Average Annual Percent Change

† Incidence per 100,000 women

‡ Expected Uterine Cancer Incidence per 100,000 women in 2020

§ Observed Uterine Cancer Incidence per 100,000 women in 2020

|| p-value less than 0.05

¶ p-value less than 0.01

p-value less than 0.001

** Data for these subgroups were insufficient in size for statistical analyses

Appendix 4. Map of the United States by Region.

